Medicine
Merck and Moderna mRNA Vaccine Slashes Melanoma Recurrence Risk
A collaborative medical innovation from pharmaceutical developers has demonstrated that an mRNA therapeutic can substantially reduce the likelihood of skin cancer recurrence. According to reporting published by Science, the treatment developed by Merck and Moderna successfully curtails melanoma returns, though researchers still face unresolved questions regarding its exact mechanism.
Giovanni Sapere
